Circulating microRNAs: novel biomark- ers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110:483 95. 80. Wong LL, Armugam A, Sepramaniam S, et al. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2015;17:393 404. 81. Ovchinnikova ES, Schmitter D, Vegter EL, et al. Signature of circulat- ing microRNAs in patients with acute heart failure. Eur J Heart Fail. 2016;18:414 23. 82. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identifi- cation of novel biomarkers and mechanisms related to common cardio- vascular diseases: form and function. Circulation. 2012;126:1110 20. 83. Cheng ML, Wang CH, Shiao MS, et al. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. J Am Coll Cardiol. 2015;65:1509 20. 84. Zheng Y, Yu B, Alexander D, et al. Associations between metabolomic compounds and incident heart failure among African Americans: the ARIC Study. Am J Epidemiol. 2013;178:534 42. 2017 ACC/AHA/HFSA Heart Failure Focused Update CLINICAL STATEMENTS AND GUIDELINES 85. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF random- ized trial. JAMA. 2013;310:66 74. 86. Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62:1365 72. 87. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic pep- tide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278 83. 88. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide pre- dicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392 7. 89. 